Document Detail

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
MedLine Citation:
PMID:  18351337     Owner:  NLM     Status:  MEDLINE    
Patients with thalassemia major requiring regular blood transfusions accumulate iron that is toxic to the heart, liver, and endocrine systems. The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP. Sixty-six patients were randomized into three treatment arms: daily DFP combined with DFO twice weekly; daily DFP only; and DFO only 5 days/week. Fifty-six patients completed the 54 weeks and were assessed by different indices. A significant reduction of liver iron concentration and serum ferritin was observed in all three arms while significant reduction of liver iron score was observed in patients on combination therapy only. Cardiac function did not significantly change in any arm. Compliance improved in patients who received combined therapy. Toxicity of DFP was mild to moderate and acceptable; most commonly, transient arthropathy and nausea/vomiting were observed. Thus, combination therapy has shown to be effective in reducing iron overload in thalassemia patients.
Amal El-Beshlawy; Chantal Manz; Mohammed Naja; Mona Eltagui; Claudia Tarabishi; Ilham Youssry; Hewida Sobh; Mona Hamdy; Iman Sharaf; Azza Mostafa; Olfat Shaker; A V Hoffbrand; Ali Taher
Related Documents :
1562027 - Increased risk of staphylococcus epidermidis peritonitis in patients on dialysate conta...
18371137 - A novel intravenous iron formulation for treatment of anemia in inflammatory bowel dise...
6097127 - Cefmenoxime in surgical infections: treatment and penetration into peritoneal fluid and...
22711347 - Long-term interferon monotherapy reduces the risk of hcv-associated hepatocellular carc...
16716757 - Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a co...
8979127 - Management of venous thromboembolism: optimization by clinical trials.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2008-03-20
Journal Detail:
Title:  Annals of hematology     Volume:  87     ISSN:  1432-0584     ISO Abbreviation:  Ann. Hematol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-05-23     Completed Date:  2008-09-18     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  545-50     Citation Subset:  IM    
Faculty of Medicine, Cairo University, 32 Falaky Street, Bab El-Louk, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Transfusion / adverse effects
Chelation Therapy / adverse effects,  methods*
Child, Preschool
Deferoxamine / administration & dosage,  adverse effects,  therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Egypt / epidemiology
Ferritins / analysis,  blood
Iron Chelating Agents / administration & dosage,  adverse effects,  therapeutic use*
Iron Overload / drug therapy*,  etiology,  prevention & control
Liver / pathology
Patient Compliance
Prospective Studies
Pyridones / administration & dosage,  adverse effects,  therapeutic use*
Thalassemia / complications,  drug therapy*,  epidemiology
Reg. No./Substance:
0/Iron Chelating Agents; 0/Pyridones; 2BTY8KH53L/deferiprone; 70-51-9/Deferoxamine; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils i...
Next Document:  Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic ...